Characteristics and outcome of immune thrombocytopenia in elderly: Results from a single center case-controlled study

American Journal of Hematology

Volumn 86, Issue 12, 2011, Pages 980-984

  Michel, Marc ^a   Rauzy, Odile Beyne ^b   Thoraval, Francoise Roudot ^c   Languille, Laetitia ^a   Khellaf, Mehdi ^a   Bierling, Philippe ^c   Godeau, Bertrand ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CHU PURPAN   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DANAZOL; DAPSONE; IMMUNOGLOBULIN; RITUXIMAB;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; AGING; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; FRANCE; HEMORRHAGE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 81355127494     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22170     Document Type: Article

References (23)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: Report from an International Working Group. Blood 2009; 113: 2386-2393.
2. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146: 585-596.
3. Portielje SE, Westendorp RG, Kluin-Nielemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554.
4. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909-913.
5. Neylon AJ, Saunders PW, Howard MR, et al. On behalf of the Northern Region Haematology Group. Northern Region Haematology group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122: 966-974.
6. Michel M. Immune thrombocytopenic purpura: Epidemiology and implications for treatment. Eur J Haematol 2009; 82(Suppl. 71): 3-7.
7. Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopahtic thrombocytopenic purpura. Blood 1991; 77: 31-33.
8. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160: 1630-1638.
9. Bizzoni L, Mazzucconi MG, Gentile M, et al. Idiopathic thrombocytopenic purpura (ITP) in the elderly: Clinical course in 178 patients. Eur J Haematol 2006; 76: 210-216.
10. Daou S, Federici L, Zimmer J, et al. Idiopathic thrombocytopenic purpura in elderly patients: A study of 47 cases from a single reference center. Eur J Intern Med 2008; 19: 47-51.
11. Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long-term results of 402 cases. Haematologica 2005; 90: 72-77.
12. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
14. Khellaf M, Michel M, Schaeffer A, et al. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than the platelet count. Haematologica 2005; 90: 829-832.
15. Le Tien V, Strého M, D'Athis P, et al. Interobserver and intraobserver reliability of detecting age-related macular degeneration using a nonmydriatic digital camera. Am J Ophtalmol 2008; 146: 520-526.
16. Stephens DM, Rupper AS, Blum KA, et al. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is feasible and not associated with adverse outcome when compared to younger patients. Blood (ASH Annual meeting Abstracts) 2010; 116: 1378.
17. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 2010; 28: 808-814.
18. Baltes PB, Smith J. New frontiers in the future of aging: From successful aging of the young old to the dilemmas of the fourth age. Gerontology 2003; 49: 123-135.
19. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost 2001; 85: 418-422.
20. Fisher M, French S, Ji P, Kim RC. Cerebral microbleeds in the elderly: A pathological analysis. Stroke 2010; 41: 2782-2785.
21. Fardet L, Flahault A, Kettaneh, et al. Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion. Br J Dermatol 2007; 157: 42-48.
22. Ahsan N. Intravenous immunoglobulin induced nephropathy: A complication of IVIG therapy. J Nephrol 1998; 11: 157-161.
23. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 2: 9-18.